2nd Edition of International Cancer & Immuno-Oncology Conference
March 19-21, 2026 | Singapore
Targeted Chemotherapy
Targeted chemotherapy represents a significant advancement in cancer treatment, offering a more precise and less harmful approach compared to traditional chemotherapy. This method involves delivering chemotherapy drugs directly to cancer cells, sparing healthy tissue from damage and reducing side effects. Through innovative techniques such as monoclonal antibodies and nanoparticles, researchers can specifically target cancer cells based on their unique characteristics, such as surface proteins or genetic mutations. By honing in on these specific targets, targeted chemotherapy not only enhances treatment efficacy but also minimizes collateral damage to the body. This tailored approach holds promise for improving patient outcomes and quality of life, ushering in a new era of precision medicine in cancer care.
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Anyou Wang
DIFIBER LLC, United States
Paulo Cesar De Morais
Catholic University of Brasilia, Brazil
Allen Chen
Olympic Medical Center, United States
Shilpa S Dhar
UT MD Anderson Cancer Center, United States
Ritu Khanna
University of Manchester, United KingdomSubmit your abstract Today
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China